Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy‑Chinese experiences.

Simple item page
dc.contributor.authorJu, Y
dc.contributor.authorHu, Y
dc.contributor.authorSun, S
dc.contributor.authorWang, J
dc.contributor.authorJiao, S
dc.date.accessioned2015-12-30T06:06:57Z
dc.date.available2015-12-30T06:06:57Z
dc.date.issued2015-11
dc.description.abstractBACKGROUND: There is not more treatment selection for advanced nonsmall‑cell lung cancer (NSCLC) patients who had disease progression after two previous treatments. Everolimus is an oral inhibitor of the mammalian target of rapamycin pathway, which is aberrantly activated in NSCLC. PATIENTS AND METHODS: Stage IV NSCLC patients, with one or multiple prior chemotherapy regimens, received everolimus 5–10 mg/day with or without chemotherapy until progression or unacceptable toxicity. The primary objective were toxicity of everolimus and overall disease control rate (DCR). RESULTS: 22 patients were enrolled. Common ≥grade3 events were stomatitis, dyspnea, vomiting, thrombocytopenia. Overall disease control rate was 54.5% among 22 patients, 1 had a partial response, and 11 had disease stabilization. Common ≥Grade 3 events were stomatitis, dyspnea, vomiting, and thrombocytopenia. CONCLUSION: Everolimus was well tolerated, showing the modest clinical activity in heavily pretreated advanced NSCLC.en_US
dc.identifier.citationJu Y, Hu Y, Sun S, Wang J, Jiao S. Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy‑Chinese experiences. Indian Journal of Cancer. 2015 Nov; 52(5)Suppl_1: s32-s36.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/169220
dc.language.isoenen_US
dc.source.urihttps://www.indianjcancer.com/article.asp?issn=0019-509X;year=2015;volume=52;issue=5;spage=32;epage=36;aulast=Juen_US
dc.subjectEverolimusen_US
dc.subjectNSCLCen_US
dc.subjecttreatmenten_US
dc.subjecttoxicityen_US
dc.titleToxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy‑Chinese experiences.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijc2015v52n5ps32.pdf
Size:
274.22 KB
Format:
Adobe Portable Document Format
Description:
Original article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Cancer